source
- Novartis signs up to $900 million deal with China's BoomRay for preclinical radioligand therapyNovartis has licensed a preclinical radioligand therapy from BoomRay Pharmaceuticals, a Suzhou‑based biotech, in a deal that could be worth up to $900 million. The agreement includes an undisclose…
- FDA issues early alert on React Health VOCSN ventilators over connector faultThe FDA's Center for Devices and Radiological Health has posted an early alert about a potential high‑risk problem with certain VOCSN ventilator units made by Ventec Life Systems, operating as Reac…